Technology
Precision Deimmunization with Our ADAx Platform
The ADAx platform is an innovative technology that incorporates proprietary CD22 ligands (CD22L) on biologics to target and suppress therapeutic-specific B cells, while preserving the full functionality of the biologic.
Our Novel Approach
Tuned Affinity & Specificity
We’ve optimized natural CD22 ligands with enhanced binding affinity and specificity, enabling precise and targeted immune modulation.
Enhanced Pharmacological Activity
Our CD22L-conjugated biologics are designed to maintain full pharmacologic function while enhancing the therapeutic profile.
Safety & Durability
Our deimmunized biologics are designed to minimize immune responses and reduce adverse events while ensuring long-term therapeutic efficacy.
Our Mechanism - ADAx Pathway
Key features of our ADAx platform
- Selectively suppresses B cell receptor (BCR) activation specific to the therapeutic while preserving normal immune responses
- Cross-species reactivity of CD22 ligand enables preclinical evaluation of ADA suppression in vivo
- Demonstrated compatibility with various protein formats including antibodies, bispecifics, multi-domain proteins, and enzymes.
- Unlike other ADA mitigation techniques, ADAx avoids broad immune suppression, does not rely on epitope masking, and does not alter the tissue distribution of the drug.